Table 1.

Clinical information and survival data

Patient ID	Sample ID	Age	Gender	Primary/metastasis	Grade	Protein expression lost	Total follow-up (months)	PFS months	OS months
ATRX/DAXX-negative tumours
1	1B2T_MG2_N	46	M	Metastasis	MG2	ATRX	54	51	54
3	3A28T2_G3_N	53	M	Primary	G3	ATRX	83	14	83
4	4A4T_G2_N	60	M	Primary	G2	DAXX	85	3	85
7	7C3T_MG1_N	81	F	Metastasis	MG1	ATRX	60	No progression	Alive
8	8A2T_G1_N	49	F	Primary	G1	DAXX	NA	NA	NA
	8A3T1_G1_N				G1	DAXX
	8A3T2_G1_N				G1	DAXX
11	11A1T_MG3_N	56	M	Metastasis	MG3	DAXX	20	16	20
12	12A3T1_MG2_N	62	F	Metastasis	MG2	DAXX	106	29	Alive
	12A9T2_MG2_N			Metastasis	MG2	DAXX
	12A10T_G2_N			Primary	G2	DAXX
13	13A12T_G2_N	73	M	Primary	G2	DAXX	55	15	Alive
	13A13T_G2_N				G2	DAXX
	13A14T_G2_N				G2	DAXX
	13A19T_G2_N				G2	DAXX
15	15A6T_G1_N	36	M	Primary	G1	DAXX	39	No progression	Alive
19	19A7T_G1_N	30	F	Primary	G1	DAXX	54	51	54
21	21A4T_G2_N	66	M	Primary	G2	ATRX	39	No progression	Alive
25	25A3T_G1_N	72	F	Primary	G1	DAXX	34	No progression	Alive
26	26A2T_G2_N	21	M	Primary	G2	DAXX	21	No progression	Alive
30	30C6T_G2_N	54	M	Primary	G2	ATRX	40	No progression	Alive
31	31A4T_G2_N	74	F	Primary	G2	ATRX	24	No progression	Alive
34	34A10T_G2_N	69	F	Primary	G2	DAXX	NA	NA	NA
35	35A7T_G1_N	23	F	Primary	G1	DAXX	56	No progression	Alive
36	36A3T_G2_N	57	M	Primary	G2	ATRX	72	14	72
37	37A3T1_G2_N	40	F	Primary	G2	ATRX	49	No progression	Alive
38	38A4T_MG1_N	84	F	Metastasis	MG1	ATRX	66	No progression	Alive
ATRX/DAXX-positive tumours
2	2B2T_G1_P	67	M	Primary	G1	No Loss	90	No progression	Alive
5	5B5T2_G1_P	60	M	Primary	G1	No Loss	84	18	Alive
6	6A6T_G1_P	51	F	Primary	G1	No Loss	68	No progression	Alive
	6A8T1_G1_P				G1	No Loss
	6A8T2_G1_P				G1	No Loss
	6A8T3_G1_P				G1	No Loss
9	9A9T2_G1_P	62	F	Primary	G1	No Loss	70	No progression	Alive
10	10A7T_G1_P	45	F	Primary	G1	No Loss	54	No progression	Alive
14	14B8T_G1_P	NA	NA	Primary	G1	No Loss	45	No progression	Alive
17	17A2T_G1_P	53	F	Primary	G1	No Loss	47	No progression	Alive
	17A4T_G1_P				G1	No Loss
18	18A4T_G1_P	64	F	Primary	G1	No Loss	40	No progression	Alive
	18A5T_G1_P				G1	No Loss
20	20A3T_MG2_P	69	F	Metastasis	MG2	No Loss	NA	NA	NA
22	22A6T_G1_P	72	M	Primary	G1	No Loss	18	No progression	Alive
23	23D2T_G1_P	54	F	Primary	G1	No Loss	28	No progression	Alive
	23D7T_G1_P				G1	No Loss
24	24A6T2_G2_P	47	F	Primary	G2	No Loss	84	36	Alive
27	27A6T_G2_P	58	M	Primary	G2	No Loss	33	No progression	Alive
28	28A8T_G2_P	66	F	Primary	G2	No Loss	18	No progression	Alive
29	29C4T_G1_P	71	F	Primary	G1	No Loss	26	No progression	Alive
32	32B4T_G1_P	26	M	Primary	G1	No Loss	126	120	Alive
33	33E13T_G1_P	58	M	Primary	G1	No Loss	26	No progression	Alive
37	37A4T_G2_P	40	F	Primary	G2	No Loss	49	No progression	Alive
	37A5T_G2_P				G2	No Loss
39	39IIFT_G2_P	58	F	Primary	G2	No Loss	162	36	Alive

PFS, progression-free survival; OS, overall survival; NA, not available. The three samples from case 37 are different regions of the same surgical pathological specimen. However, because of intra-tumoral heterogeneity, we observed that one sample was ATRX-negative, whereas the remaining two were ATRX/DAXX-positive. For this reason, case 37 was not considered in the survival analysis.